Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-HEC585 in Healthy Chinese Male Subjects
NCT05468346Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yifenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Sunshine Lake Pharma. Primary endpoint: Mass balance up to 504 hours. Started Jul 2022; status: completed.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05468346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468346.